购物车
- 全部删除
- 您的购物车当前为空
Etoricoxib (MK-663) 是一种合成的非甾体抗炎药 (NSAID),具有解热、镇痛和潜在的抗肿瘤特性。它是可口服的选择性 COX-2抑制剂,对人全血 COX-2 和 COX-1 的 IC50值分别为 1.1 和 116 μM。
Etoricoxib (MK-663) 是一种合成的非甾体抗炎药 (NSAID),具有解热、镇痛和潜在的抗肿瘤特性。它是可口服的选择性 COX-2抑制剂,对人全血 COX-2 和 COX-1 的 IC50值分别为 1.1 和 116 μM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | ¥ 118 | 现货 | |
10 mg | ¥ 197 | 现货 | |
25 mg | ¥ 317 | 现货 | |
50 mg | ¥ 461 | 现货 | |
100 mg | ¥ 792 | 现货 | |
500 mg | ¥ 1,990 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 136 | 现货 |
产品描述 | Etoricoxib (MK-663) is a synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis. |
靶点活性 | COX-2:1.1 μM COX-1 |
体内活性 | 环氧合酶-2抑制剂etoricoxib显著降低了phenytoin的抗惊厥作用,并显著增强了diazepam对小鼠模型中最大电休克和戊四氮诱导的惊厥的有益作用[1]。Etoricoxib有作为结肠抗凋亡和抗增殖剂的潜力[2]。 |
细胞实验 | Human colon carcinoma cell line HCT-116 are treated with various coxibs for 2 h. Subsequently, the cells are harvested and the sphingolipids isolated and determined by LC-MS/MS. (Only for Reference) |
别名 | Arcoxia, MK-663, Tauxib, L-791456, Nucoxia, Desvenlafaxine, 依托考昔 |
分子量 | 358.84 |
分子式 | C18H15ClN2O2S |
CAS No. | 202409-33-4 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | Ethanol: 43 mg/mL (119.8 mM) DMSO: 50 mg/mL (139.34 mM) H2O: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.